Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVigil Neuroscience Inc

Vigil Neuroscience Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-09-04T20:10:46.930510Z
Market Cap
124.40M

Momentum Score

…

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.50
Low
11.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
8.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.12
ROE
-60.18%
Net Debt
-38.14M
ROCE
-53.38%
Diluted EPS TTM
-1.92

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -68.31M -43.28M -
Net income -67.73M -43.25M -
Selling general administrative 21.44M 10.08M -
Reconciled depreciation 0.08M 0.03M -
Ebit -68.96M -42.44M -12.58M
Ebitda -68.88M -42.41M -
Depreciation and amortization 0.08M 0.03M -
Non operating income net other 0.58M - -
Operating income -68.88M -42.41M -
Other operating expenses 68.88M 42.41M -
Interest expense -0.08M 43.26M 0.00M
Interest income 0.62M 0.00M -
Net interest income 0.62M 0.00M -
Income tax expense -0.58M -0.03M -
Total revenue 0.00M 0.00M -
Total operating expenses 68.88M 42.41M -
Total other income expense net 0.58M -0.87M -
Net income from continuing ops -68.31M -43.28M -
Net income applicable to common shares -68.31M -43.28M -57.09M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 140.86M 200.39M 102.44M 25.30M
Other current assets 2.48M 0.63M 0.47M 0.07M
Total liab 24.61M 11.31M 171.88M 53.58M
Total stockholder equity 116.25M 189.08M -69.44M -28.28M
Deferred long term liab - - 2.76M -
Other current liab 8.81M 9.19M 0.12M 0.89M
Common stock 0.00M 0.00M - 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M
Retained earnings -222.77M -140.13M -71.83M -28.55M
Other liab - - - 4.25M
Other assets - 1.19M 3.68M -
Cash 51.99M 186.60M 91.42M 24.15M
Total current liabilities 11.66M 11.31M 9.88M 2.00M
Current deferred revenue - - 4.92M -
Net debt -38.14M -186.43M -90.48M -24.15M
Short term debt 0.91M 0.18M 0.87M -
Short long term debt total 13.85M 0.18M 0.94M -
Other stockholder equity 339.02M 128.82M -69.94M 0.26M
Property plant equipment - 1.18M 1.27M -
Total current assets 121.91M 197.81M 97.48M 25.30M
Net tangible assets - 189.08M -69.44M -28.28M
Short term investments 65.95M - - -
Net receivables 1.49M - - -
Accounts payable 1.95M 1.94M 3.98M 1.11M
Accumulated other comprehensive income -0.01M - - -
Common stock total equity - 0.00M - -
Retained earnings total equity - -140.13M - -
Non currrent assets other 0.08M 1.19M 3.68M -
Non current assets total 18.95M 2.59M 4.96M 0.00M
Capital lease obligations 13.85M 0.18M 0.94M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.92M -0.20M -
Change to liabilities 1.52M 2.35M 2.21M
Total cashflows from investing activities -0.92M -0.20M -1.00M
Net borrowings -0.04M -0.04M 10.00M
Total cash from financing activities 161.25M 107.75M 59.66M
Change to operating activities -0.85M -1.71M -0.51M
Net income -68.31M -43.28M -57.09M
Change in cash 95.19M 68.20M 48.30M
Begin period cash flow 92.35M 24.15M -
End period cash flow 187.53M 92.35M 24.15M
Total cash from operating activities -65.15M -39.35M -10.36M
Issuance of capital stock 140.47M 109.63M -
Depreciation 0.08M 0.03M 0.03M
Sale purchase of stock 161.30M - -
Other cashflows from financing activities 20.83M 87.91M -1.89M
Change to netincome 5.48M 3.27M 45.03M
Capital expenditures 0.92M 0.20M 0.20M
Cash flows other operating -3.92M - -
Cash and cash equivalents changes 95.19M - -
Change in working capital -3.33M 0.64M -
Stock based compensation 5.48M 2.08M -
Other non cash items 0.93M 1.18M -
Free cash flow -66.07M -39.55M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Vigil Neuroscience Inc

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

100 Forge Road, Watertown, MA, United States, 02472

857 254 4445

https://www.vigilneuro.com

65

Name Title Year Born
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. Pres, CEO & Director 1967
Ms. Jennifer Ziolkowski CPA, CPA Chief Financial Officer 1974
Dr. Spyridon Papapetropoulos M.D., Ph.D. Chief Medical Officer 1973
Park Guo CPA Accounting Mang. NA
Kelly Neelon Ph.D. VP of CMC & Technical Operations NA
Ms. Sarah Carmody VP of Investor Relations & Corp. Communications NA
Mr. Christopher Verni J.D. Gen. Counsel 1975
April Effort M.B.A., M.S. Head of Corp. Devel. NA
Mr. Evan A. Thackaberry DABT, Ph.D. Sr. VP & Head of Early Devel. 1973
Mr. Charles Maggs Head of FP&A NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…